<DOC>
	<DOCNO>NCT01144676</DOCNO>
	<brief_summary>The propose study single-center , double-blind , randomise , placebo-controlled trial evaluate delivery dapivirine matrix vaginal ring 56 57 day period ass safety compare placebo vaginal ring 48 healthy , HIV-negative , sexually active woman .</brief_summary>
	<brief_title>A Safety Study Assess Delivery Dapivirine From Matrix Vaginal Ring</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women ≥18 ≤40 year age give write informed consent ; Available visit consent follow procedure schedule trial ; Healthy selfreported sexually active ( defined average one penetrative penile vaginal coital act per month 3 month prior enrolment ) ; Be stable form contraception , define : A stable oral contraceptive regimen least 2 month prior enrolment , OR , Transdermal contraceptive patch least 3 month prior enrolment , OR , Longacting progestin least 6 month prior enrolment , OR , An IUD insert ( vaginal gynaecological complaint associate use ) least 3 month prior enrolment , OR , Have undergone surgical sterilization least 3 month prior enrolment ; In absence use exogenous hormone ( ) , selfreported regular menstrual cycle , define minimum 21 day maximum 35 day menses ; Upon pelvic examination colposcopy time enrolment , cervix vagina appear normal determined Investigator ; Asymptomatic genital infection time enrolment ( woman diagnose treatable STI , either syndromically laboratory test time screening , must receive treatment least 2 week prior enrolment ) ; Willing refrain use vaginal product object include , female condom , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche , lubricant , vibrators/dildos , dry agent 14 day prior enrolment duration trial . Tampon use permit ; Willing use oral contraceptive avoid menstruation , necessary take part trial ; Documentation abnormality Pap test , include grossly bloody smear , within 90 day prior screen ; Willing refrain participation research trial duration trial ; Willing provide adequate locator information trial retention purpose reachable per local standard procedure [ e.g. , home visit telephone ; via family close neighbour contact ( confidentiality maintain ) ] ; Willing agree abstain follow criterion total 2 day ( 48 hour ) prior trial visit , well total 3 day ( 72 hour ) biopsy procedure : Vaginal intercourse Oral contact genitalia Hepatitis B C negative time enrolment . Currently pregnant last pregnancy outcome within 3 month prior screen ; Currently breastfeed ; Currently within two month participation clinical research trial involve investigational market product prior screen ; Untreated symptomatic urogenital infection , e.g. , urinary tract sexually transmitted infection , gynaecological condition vaginal itching , pain , discharge , within 2 week prior enrolment ; Presence abnormal clinically significant physical finding vulva , vaginal wall cervix pelvic examination and/or colposcopy preenrolment ; History urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence ; Current vulvar vaginal symptom / abnormality could influence trial result ; Pap test result require cryotherapy , biopsy , treatment ( infection ) ; evaluation [ include finding atypical squamous cell undetermined significance ( ASCUS ) ] ; Symptomatic genital HSV infection history genital herpetic infection ; Any Grade 2 , 3 4 haematology , chemistry urinalysis laboratory abnormality baseline ( screen ) accord DAIDS Table Grading Adverse Events ( NOTE : This table find : http : //rcc.techres.com/safetyandpharmacovigilance ; standardize version provide research centre Study Operations Manual ) ; Unexplained , abnormal bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrolment ; Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone ; Any serious acute , chronic progressive disease ( e.g. , known history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , HIV , AIDS , blood dyscrasia ) , sign cardiac disease , renal failure , severe malnutrition ; Have undergone hysterectomy ; Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>